JTK-109 is a thumb 1 binding RNA-directed RNA polymerase (NS5B) inhibitor potentionally used for the treatment of HCV infection. JTK-109 also inhibits G1b and G3a subgenomic replicons and recombinant enzymes but was 41-fold less active against the G2a replicon. References: Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem. 2006 Jul 27;49(15):4721-36. PubMed PMID: 16854079.

纯度：≥98%

CAS：480462-62-2